RCAP
RGNX icon

Resolute Capital Asset Partners’s Regenxbio RGNX Stock Holding History

Resolute Capital Asset Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,000
Closed -$843K – 60
2024
Q1 		$843K Buy
+40,000
New +$712K 0.44% 42

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Resolute Capital Asset Partners's RGNX Position: Q2 2024 in Review

Resolute Capital Asset Partners sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 40,000 shares — an estimated $843K sold.

Resolute Capital Asset Partners first reported a position in RGNX in Q1 2024 and held it in 1 quarter. The position peaked at $843K in Q1 2024. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

  • Resolute Capital Asset Partners reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 40,000 Regenxbio shares in Q2 2024, an estimated $843K.
  • Resolute Capital Asset Partners first reported a position in Regenxbio in Q1 2024 and held it in 1 quarter.
  • Resolute Capital Asset Partners's Regenxbio position peaked at $843K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2024, filed 12 Aug 2024.